Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.


Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by Reaxense.


In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.


Our library distinguishes itself through several key aspects:


  • The Receptor.AI platform integrates all available data about the target protein, including past experiments, literature data, known ligands, structural information and more. This consolidated approach maximises the probability of prioritising highly relevant compounds.

  • The platform uses sophisticated molecular simulations to identify possible binding sites so that the compounds in the focused library are suitable for discovering allosteric inhibitors and the binders for cryptic pockets.

  • The platform integrates over 50 highly customisable AI models, which are thoroughly tested and validated on a multitude of commercial drug discovery programs and research projects. It is designed to be efficient, reliable and accurate. All this power is utilised when producing the focused libraries.

  • In addition to producing the focused libraries, Receptor.AI provides services and end-to-end solutions at every stage of preclinical drug discovery. The pricing model is success-based, which reduces your risks and leverages the mutual benefits of the project's success.


PARTNER
Receptor.AI
 
UPACC
Q96QS6

UPID:
PSKH2_HUMAN

ALTERNATIVE NAMES:
Protein serine kinase H2

ALTERNATIVE UPACC:
Q96QS6; A0AV22

BACKGROUND:
The Serine/threonine-protein kinase H2, with alternative names such as Protein serine kinase H2, is integral to the phosphorylation of serine and threonine amino acids. This post-translational modification is pivotal for the regulation of various cellular activities, including the cell cycle, apoptosis, and the repair of DNA damage.

THERAPEUTIC SIGNIFICANCE:
Exploring the functions of Serine/threonine-protein kinase H2 holds the potential to unlock novel therapeutic avenues. Given its central role in critical cellular processes, targeting this kinase could lead to innovative treatments for conditions characterized by aberrant cell growth and survival.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.